Around half a million Australians use GLP-1 medications for diabetes – and when you add people who use it for obesity and weight-related conditions, the total is much higher.
GLP-1s – such as semaglutide (Ozempic or Wegovy) and tirzepatide (Mounjaro) – are very effective at managing diabetes, obesity and metabolic or weight-related health conditions.
